A small ubiquitin-like protein was shown to be beneficial to the failing heart through enhancing sarcoplasmic reticulum Ca 2+ ATPase 2a (SERCA2a) stability and activity in a large animal model of heart failure.
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A small ubiquitin-like protein was shown to be beneficial to the failing heart through enhancing sarcoplasmic reticulum Ca 2+ ATPase 2a (SERCA2a) stability and activity in a large animal model of heart failure.
Dysregulation of calcium cycling in cardiomyocytes has been recognized as a major molecular mechanism of heart failure. SERCA2a plays a pivotal role in regulating calcium homeostasis, and reduction of SERCA2a activity has been recognized as a hallmark of heart failure. Hajjar and his colleagues 1 reported that the activity of SERCA2a is regulated by conjugation of small ubiquitin-like modifier-1 (SUMO-1) to SERCA2a. They also demonstrated that SUMO-1 gene delivery can restore SERCA2a expression and activity in the failing heart in a mouse model. Based on these findings, they postulated that SUMO modification (SUMOylation) is a critical regulator of SERCA2a function, which led to the design of SUMO-1 gene therapy in a swine ischemia-reperfusion heart failure model. 2 The authors performed a temporary balloon occlusion of the proximal left anterior descending artery to create myocardial infarction. One month later, 31 survived pigs were randomized to receive via antegrade coronary infusion either saline or adeno-associated vector type 1 (AAV1) loaded with SUMO-1 (low and high dose), SERCA2a, or both. They showed that both SUMO-1 and SERCA2a levels were increased in the pigs that received AAV1.SUMO-1 with or without AAV1.SERCA2a 2 months later. However, the changes in left ventricular ejection fraction (EF) were not statistically significant in all treated groups. Statistically significant changes were demonstrated in the maximal rate of pressure rise [dP/dt(max)] in the groups that received high-dose SUMO-1, SERCA2a, or both. Furthermore, the treated groups have less left ventricular dilatation. The authors concluded that SUMO-1 gene either alone or in combination with SERCA2a is beneficial in a large animal model of heart failure and holds promise for the treatment of heart failure in humans.
SERCA2a is a calcium-ion pump that takes up calcium from the cytosol into the sarcoplasmic reticulum. 3 The expression level and activity of SERCA2a were found to be diminished in the failing heart. 4 In contrast to the well-known SERCA2a, SUMO is relatively unknown to the cardiovascular research community. SUMO belongs to a family of ubiquitinlike proteins that covalently attached to a large number of cellular proteins. SUMOylation is a versatile post-translational protein modification system that regulates a protein's cellular localization, function, and stability. 5 There are 3 different SUMOs: SUMO-1, SUMO-2, and SUMO-3 ( Figure) . SUMO-2 and SUMO-3 are closely related and are usually described as SUMO-2/3. SUMO-1 usually modifies its substrate as a monomer, whereas SUMO-2 or SUMO-3 can build up poly-SUMO chains. Similar to phosphorylation and dephosphorylation, SUMO modification can be removed by a family of Sentrin/SUMO-specific proteases. 
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Commentaries Figure. SUMOylation and de-SUMOylation. SUMO modification is a dynamic process that regulates many biological functions. The conjugation of SUMO to the target proteins required the activating enzyme (E1), conjugating enzyme (E2), and ligating enzyme (E3). SUMO/Sentrin-specific proteases (SENPs) deconjugate SUMO from SUMO-conjugated proteins. DRP1 indicates dynamin-related protein 1; ERK5, extracellular signal-regulated kinase 5; GATA4, GATA binding protein 4; MEF2C, myocyte enhancer factor 2C; NKX2.5, NK2 homeobox 5; PGC-1α, peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PPARα, peroxisome proliferator-activated receptor alpha; PPARγ, peroxisome proliferator-activated receptor gamma; SERCA2a, sarcoplasmic reticulum Ca 2+ ATPase 2a; and SRF, serum response factor.
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May 9, 2014 in cell biology, including development, DNA replication/repair, and the hypoxic response. [6] [7] [8] Interestingly, several cardiac transcription factors are SUMOylated and their transcriptional activities are altered by SUMOylation. 9 The authors first demonstrate that AAV1.SUMO-1 restores the expression of SUMO-1 and SERCA2a in the failing heart. This occurs at both the mRNA and protein levels. Furthermore, SUMOylated SERCA2a is markedly increased in the group that received both SUMO-1 and SERCA2a. This is because of the persistence of AAV1 in the cardiac tissues 2 months after gene delivery. Despite restoration of SUMO-1 and SERCA2a expression, changes in EF only showed a trend toward improvement in the high-dose SUMO-1 group as compared with control but did not reach statistically significance. The authors argued that the improvements on the molecular level may precede the functional benefits. One wonders whether a longer observation period could demonstrate a statistically significant improvement in the EF in the treated group.
Hajjar and his colleagues 10 previously reported in a phase 1/2 human gene therapy trial using AAV1.SERCA2a that patients treated with high-dose SERCA2a have marked reduction in all-cause mortality. The number of cardiovascular events, such as myocardial infarction, worsening heart failure, ventricular assist device placement, cardiac transplantation, and death, was also reduced in the low-and mid-dose group as compared with placebo control. However, EF was not reported in the 3-year follow-up but was not statistically significant at 12-month follow up. 10, 11 Thus, EF improvement was not seen in either SERCA2a-or SUMO-1-based gene therapy in human. If EF changes are not significant in both the animal model and the human studies, how does SERCA2a or SUMO-1 gene therapy benefits the failing heart? In this article, the authors showed that there was a statistically significant improvement in cardiac contractility as measured by dP/dt(max) and left ventricular volume. 2 Thus, the mechanism whereby SUMO-1 gene therapy benefits the failing heart may be because of a beneficial effect on cardiac remodeling. It is more difficult to explain why improvement in contractility failed to translate into a better EF. Perhaps, the number of the animals studied was too small to reach that conclusion.
The authors provided limited analysis on the mechanisms whereby SUMO-1 gene therapy exerted its beneficial effect. They showed that specificity protein 1 (SP1), a transcription factor for SERCA2a, is markedly increased in the saline group but returned toward normal in the treated group, and SUMOylated SP1 is increased in high-dose SUMO-1-treated group. They suggested that the increase in SUMOylated SP1 is responsible for the increase in SERCA2a mRNA in the treated groups. In contrast to the increase in the stability of SUMOylated SERCA2a, SUMO-1-modified SP1 actually leads to its degradation in a ubiquitin-dependent manner. 12 SUMOylated SP1 was shown to be localized in the cytosol and thus will not enhance transcription. In another study, SUMOylation has been shown to inhibit the cleavage of the SP1 N-terminal negative regulatory domain and SP1-dependent transcription. 13 Thus, the increase in SUMOylated SP1 in the SUMO-1-treated group could not account for the increase in SERCA2a mRNA. It is more likely that SUMO-1 increases the stability of SERCA2a directly and enhances its ATPase activity as shown by the authors' previous report. 1 SUMO-1 can modify many cellular proteins and could exert its beneficial effect in the failing heart in >1 way. The authors showed that the proform of caspase 3 is reduced in the treated group. One possible scenario is that SUMO-1 may exert an antiapoptotic effect on the dying cardiomyocytes. Interestingly, SUMO-1 was identified originally by us as Sentrin, a protein that protected cell from Fas ligand or tumor necrosis factormediated apoptosis. 14 We showed that SUMO-1 binds to the death domains of both FAS and tumor necrosis factor receptor and prevents signaling leading to apoptosis. Thus, overexpression of SUMO-1 could protect the cardiomyocytes from cell death, which could reduce cardiac remodeling and preserve cardiac contractility.
An important question to be answered is why SUMO-1 expression is lowered in the failing heart. Additional research is necessary to identify the signaling pathway and transcription factors that are involved in the downregulation of the SUMO-1 gene transcription. It would be much easier to use a small molecule to increase the transcription of SUMO-1 in lieu of SUMO-1 gene therapy. The authors have shown previously that SUMOylation prevents the degradation of SERCA2a. 1 Thus, another potential therapeutic approach is to block SERCA2a degradation with a proteasome inhibitor. Indeed, proteasome inhibitors have been shown to exert a beneficial effect on the failing heart. 15 The downside of the proteasome inhibitor approach is the lack of specificity and potential pleiotropic effects. If the goal is to increase SUMOylation of SERCA2a, one can reduce the expression and activity of Sentrin/SUMO-specific proteases that are specific for SERCA2a. Alternatively, one can increase the expression and activity of a SERCA2a-specific E3 ligase. In summary, Tilemann and his colleagues 2 have introduced an innovative approach to treat heart failure. Although additional investigations are required, we are hopeful that SUMO-1 gene therapy or strategies to increase SUMO-1 level may provide new therapy for patients with heart failure in the future.
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